Implementing the Dementia Early Stage Cognitive Aids New Trial (DESCANT) intervention: mixed-method process evaluation alongside a pragmatic randomised trial.

Dementia intervention mixed methods pragmatic randomised trial process evaluation

Journal

Aging & mental health
ISSN: 1364-6915
Titre abrégé: Aging Ment Health
Pays: England
ID NLM: 9705773

Informations de publication

Date de publication:
Apr 2022
Historique:
pubmed: 14 1 2021
medline: 26 4 2022
entrez: 13 1 2021
Statut: ppublish

Résumé

The DESCANT (Dementia Early Stage Cognitive Aids New Trial) intervention provided a personalised care package designed to improve the cognitive abilities, function and well-being of people with early-stage dementia and their carers, by providing a range of memory aids, together with appropriate training and support. This sub-study aimed to assess implementation and identify contextual factors potentially associated with participant outcomes. A mixed-methods approach was adopted alongside the pragmatic randomised trial. Data were obtained from intervention records and interviews with five dementia support practitioners across seven National Health Service Trusts in England and Wales. A reporting framework was constructed from available literature and data assessed by descriptive statistics and thematic analysis. Participation and engagement was high with 126 out of 128 participants completing the intervention with packages tailored to individual participants. Misplacing items and poor orientation to date and time were common areas of need. Memory aids frequently supplied included orientation clocks (91%), whiteboards (60%), calendars (43%) and notebooks (32%), plus bespoke items. Intervention duration and timing were broadly consistent with expectations. Variation reflected participants' needs, circumstances and preferences. Qualitative findings suggested a potentially positive impact on the well-being of people with dementia and their carers. Issues associated with successful roll-out of the intervention are explored in the discussion. Successful implementation increased confidence in future findings of the randomised trial. Depending on these, DESCANT may prove a scalable intervention with potential to improve the function and quality of life of people with dementia and their carers.

Identifiants

pubmed: 33438441
doi: 10.1080/13607863.2020.1870204
doi:

Types de publication

Journal Article Pragmatic Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

667-678

Subventions

Organisme : Department of Health
ID : DTC-RP-PG-0311-12003
Pays : United Kingdom

Auteurs

Helen Chester (H)

Institute of Mental Health, School of Medicine, The University of Nottingham, Nottingham, UK.

Rebecca Beresford (R)

Social Care and Society, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.

Paul Clarkson (P)

Social Care and Society, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.

Charlotte Entwistle (C)

Department of Psychology, Fylde College, Lancaster University, Lancaster, UK.

Vincent Gillan (V)

Social Care and Society, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.

Jane Hughes (J)

Institute of Mental Health, School of Medicine, The University of Nottingham, Nottingham, UK.

Martin Orrell (M)

Institute of Mental Health, School of Medicine, The University of Nottingham, Nottingham, UK.

Rosa Pitts (R)

Division of Health Research, Faculty of Health and Medicine, Lancaster University, Lancaster, UK.

Ian Russell (I)

Swansea Trials Unit, Medical School, Swansea University, Swansea, Wales.

Eileen Symonds (E)

Institute of Mental Health, School of Medicine, The University of Nottingham, Nottingham, UK.

David Challis (D)

Institute of Mental Health, School of Medicine, The University of Nottingham, Nottingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH